Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets falls 40.6% from a year ago
Other current assets stood at $5.16M at the end of Q1 FY2026, down 40.6% from a year earlier and down 28.8% from the prior quarter. Over 3 fiscal years it compounded at +374.2% a year.
Context
- Other current assets amounted to 0.9% of total assets at the end of Q1 FY2026, down 0.9 pp from a year earlier.
- Other current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -40.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 7.25M USD
- Year-over-year change
- -43.4%
- 3-year CAGR
- +374.2%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.25M | -43.4% |
| FY2024 | 2024-12-31 | 12.82M | +12722.0% |
| FY2023 | 2023-12-31 | 100K | +47.1% |
| FY2022 | 2022-12-31 | 68K | — |
Other Current Assets vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 other current assets of $5.16M is the 3rd highest of the 6 companies compared; the peer median is $3.99M.
- Its year-over-year change of -40.6% is the 5th highest of 6, against a peer median of +4.9%.
- Other current assets amounts to 0.9% of total assets for BCAX, versus a peer median of 2.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $9.52M | -31.7% | +7.3% | 2.4% | |
| Mar 2026 | $8.37M | +4.9% | -4.9% | 3.8% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $5.16M | -40.6% | +374.2% | 0.9% |
| Mar 2026 | $3.99M | +18.0% | +0.0% | 6.8% | |
| Mar 2026 | $1.37M | +1643.2% | — | 0.7% | |
| Mar 2026 | $1M | -91.3% | -51.9% | 0.5% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $3.99M | +4.9% | -2.4% | 2.4% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.